Samumed CMO Hopes To Reach Drug Approvals Via The Wnt Pathway

 
• By Sten Stovall

The clinical-stage biotech has diverse pipeline generated by its Wnt signalling pathway technology platform, and aims to get its first drug to market in 2020.

Mouse Dvl-1 DEP
Sumumed's investigational drugs target disease driven by mutations in the Wnt signaling pathway • Source: Shutterstock

More from Strategy

More from Business